This article talks about the reaction to Gilead's announced price point on the new 1-A-Day HIV med. Wait for it, Da da DA!!! Stribild soon saelling for only $28,500 annually. There's no way federally funded programs like ADAP can withstand such a price. Especially when this company is impart responsible for other regimens like Atripla & a Truvada cocktail, that work nearly as well for much, much less.
Gilead has knocked the price point up in an attempt to amass revenue before facing an onslaught by generics in the coming years. Gilead tried to appease people by allowing some of their formulas to be used for generic production in low-income countries. I'm so sick of that. This is an American company, it'd be nice if an American firm actually gave Americans the best price.
Add to that, most + people in the world share some traits. They are often ethnic, poor, alienated & marginalized. With that said, I don't see how any one, any where, is more deserving of a good price on HIV meds than any one else. The HIV rates in the Southern USA are astounding & a huge number of those people live in utter poverty.
I hope the federal programs refuse to cover this 4-in-1 & sticks to other regimens. Gilead is trying to squeeze blood from a turnip here. It's pharma companies like this one, that make people distrust all of them. BTW, Gilead, if you do amass your great revenue via this drug, I hope you choke on it.
Cya...
No comments:
Post a Comment